Technical Analysis for CRVS - Corvus Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Up 3 Days in a Row | Strength | 0.00% | |
| Shooting Star Candlestick | Bearish | 2.37% | |
| NR7 | Range Contraction | 2.37% | |
| Wide Bands | Range Expansion | 2.37% | |
| 20 DMA Support | Bullish | 2.86% | |
| Bullish Engulfing | Bullish | 2.86% | |
| Wide Bands | Range Expansion | 2.86% | |
| 20 DMA Support | Bullish | 6.93% | |
| Wide Bands | Range Expansion | 6.93% | |
| Down 3 Days in a Row | Weakness | 6.93% |
| Alert | Time |
|---|---|
| Possible NR7 | 1 day ago |
| Shooting Star Candlestick Entry | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| 10 DMA Resistance | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/13/2024
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Immune Checkpoint Adenosine Oncology Therapies Cd73
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Immune Checkpoint Adenosine Oncology Therapies Cd73
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.19 |
| 52 Week Low | 1.05 |
| Average Volume | 250,365 |
| 200-Day Moving Average | 1.79 |
| 50-Day Moving Average | 1.81 |
| 20-Day Moving Average | 2.09 |
| 10-Day Moving Average | 2.14 |
| Average True Range | 0.17 |
| RSI (14) | 59.84 |
| ADX | 18.25 |
| +DI | 19.31 |
| -DI | 16.68 |
| Chandelier Exit (Long, 3 ATRs) | 1.84 |
| Chandelier Exit (Short, 3 ATRs) | 1.94 |
| Upper Bollinger Bands | 2.37 |
| Lower Bollinger Band | 1.80 |
| Percent B (%b) | 0.63 |
| BandWidth | 27.23 |
| MACD Line | 0.09 |
| MACD Signal Line | 0.11 |
| MACD Histogram | -0.0143 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.31 | ||||
| Resistance 3 (R3) | 2.30 | 2.25 | 2.29 | ||
| Resistance 2 (R2) | 2.25 | 2.21 | 2.25 | 2.28 | |
| Resistance 1 (R1) | 2.20 | 2.18 | 2.23 | 2.21 | 2.27 |
| Pivot Point | 2.15 | 2.15 | 2.16 | 2.15 | 2.15 |
| Support 1 (S1) | 2.10 | 2.11 | 2.13 | 2.11 | 2.05 |
| Support 2 (S2) | 2.05 | 2.08 | 2.05 | 2.04 | |
| Support 3 (S3) | 2.00 | 2.05 | 2.04 | ||
| Support 4 (S4) | 2.01 |
